Profile

Benedict Lum

Dr. Benedict Lum joined ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) in Apr 2025 as a Postdoctoral Research Fellow. Benedict is a translational cell biologist with strong research background in cancer biology, cellular trafficking, immuno-oncology, monoclonal antibody drugs, humanised patient derived xenograft mice models and theranostics.

Benedict earned his PhD from the University of Queensland in 2023 at the Frazer institute. Under the supervision of Prof. Fiona Simpson, he studied how temporary inhibition of target receptor endocytosis can improve the delivery and efficacy of targeted therapies such as antibody-drug conjugates (ADCs) and radiopharmaceuticals. There, he also performed extensive work in the space of immuno-oncology to understand how these drugs interact with the immune system and the tumour microenvironment. Some of his works have now been published in class-leading scientific journals such as Cell and Nature Reviews Cancer.

During his postdoctoral studies at the UQ Frazer institute, Benedict continued to pursue his work on endocytosis inhibition in cancer on PSMA-targeted radiopharmaceuticals in partnership with Telix Pharmaceuticals. In his current role at the AMTAR research hub, Benedict will be continuing his research partnership with Telix Pharmaceuticals to research and develop next-generation radiopharmaceuticals.



View All People